Lemanske 2004.

Methods	DESIGN: randomised, double‐blind clinical trial
Participants	SYMPTOMATIC PARTICIPANTS RANDOMLY ASSIGNED: 205 WITHDRAWALS: not reported AGE: median (years) (range): 4 to 9 years GENDER: N (male %): not reported ASTHMA SEVERITY ASTHMA DURATION: median (months) (range): not reported MEAN (± SD) β2‐AGONIST USE (puffs/d): median (months) (range): not reported DOSE OF ICS AT STUDY ENTRY AND AT RUN‐IN: not reported ATOPY (% of participants): not reported ELIGIBILITY CRITERIA: not reported EXCLUSION CRITERIA: not reported
Interventions	PROTOCOL DURATION Run‐in = not reported Intervention = 48 weeks DEVICE: metered‐dose inhaler DOSE OF ICS INTERVENTION: mometasone furoate 100 μg/d CONTROL: mometasone furoate 200 μg/d CRITERIA FOR WITHDRAWAL FROM STUDY:
Outcomes	ANALYSIS: Efficacy was assessed on an intent to‐treat (ITT) basis; between‐group differences in changes from baseline in the primary variable were also evaluated in the per‐protocol population. Primary and secondary spirometry data and diary data were fit with an analysis of co‐variance (ANCOVA) model; results of urine cortisol analysis were summarised with descriptive statistics OUTCOMES GROWTH MEASUREMENT TECHNIQUE: stadiometric height measured and growth velocities calculated PULMONARY FUNCTION TESTS PEFR FUNCTIONAL STATUS Growth velocity Bone age Bone metabolism Ophthalmic examination Asthma control BIOMARKERS Plasma and urine cortisol ADVERSE EVENTS: reported WITHDRAWALS: not reported
Notes	PUBLICATION: abstract; full paper not found FUNDING: not reported CONFIRMATION OF METHODOLOGY: not received
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	The trial was randomised but the randomisation technique was not mentioned
Allocation concealment (selection bias)	Unclear risk	No details reported
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double‐blind
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Incomplete reporting of details for judgement
Selective reporting (reporting bias)	Low risk	Primary and secondary outcomes described
Other bias	Low risk	No apparent risk of bias noted